** Danaher DHR.N beat Wall Street estimates for first-quarter profit on Tuesday, and said it expects to incur additional tariff-related costs of about $350 million this year

** Median PT of brokerages covering the stock is $246.50, per data compiled by LSEG

ABLE TO NAVIGATE TOUGH ENVIRONMENT

** Leerink Partners ("outperform", PT:$230) says it sees DHR as the leader in the recurring revenue market of bioprocess tools

** William Blair ("outperform") says Danaher is well insulated from broader macro headwinds (e.g., weaker U.S. academic and government market, slowdown in biotech funding, tariffs)

** Evercore ISI ("outperform", PT:$230) says underlying order momentum and backlog build was a solid data point that suggests order patterns normalizing

** RBC Capital Markets ("outperform," PT:$250) says DHR's positive Q1 results provides a much-needed piece of good news for the sector

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))